@article{MTMT:31187860, title = {Nagysejtes neuroendocrin carcinoma - a kórisme és a kezelés nehézségei [Large-cell neuroendocrine carcinoma of the lung - challenges of diagnosis and treatment]. [esetismertetés]}, url = {https://m2.mtmt.hu/api/publication/31187860}, author = {Zombori, Tamás and Juhász-Nagy, Gréta and Tiszlavicz, László and Cserni, Gábor and Furák, József and Szalontai, Klára Margit and Pálföldi, Regina}, doi = {10.1556/650.2020.31581}, journal-iso = {ORV HETIL}, journal = {ORVOSI HETILAP}, volume = {161}, unique-id = {31187860}, issn = {0030-6002}, abstract = {Abstract: Small-cell lung carcinoma (SCLC) and the rare large-cell neuroendocrine carcinoma belong to the high grade pulmonary neuroendocrine carcinomas. Making the correct diagnosis and selection of treatment modalities require multidisciplinary meetings due to the morphological overlaps, aggressive behaviour and debated therapeutic guidelines of these entities. A 52-year-old woman was admitted to the hospital because of headache, nausea and tenebrous vision. The CT revealed metastatic tumour mass in the occipital lobe and in the cerebellum. Both tumours were removed and resulted in histological diagnosis of metastatic neuroendocrine carcinoma. Chest X-ray established contrast-enhancing lesion in the left lung. Bronchoscopy was performed and histological examination revealed large-cell neuroendocrine carcinoma. Postoperative skull irradiation and small-cell lung cancer chemotherapy protocol were utilized. Due to atelectasis and progression, chest irradiation was initiated, which was interrupted because of novel brain metastases. Further chemotherapy followed the non-small-cell lung cancer protocol. After 3 months, thoracic progression, brain and disseminated bone metastases were diagnosed. After a 14-month-long therapy, the patient deceased. Large-cell neuroendocrine carcinoma has a poor prognosis, the incidence of brain metastasis is 25?50%. In early stage large-cell neuroendocrine carcinoma, lobectomy is the standard treatment and adjuvant chemotherapy should also be considered. Although the non-small-cell lung cancer chemotherapy protocol is approved widely in the treatment of large-cell neuroendocrine carcinoma, the utility of SCLC scheme has also been suggested. Orv Hetil. 2020; 161(8): 313?319.}, year = {2020}, eissn = {1788-6120}, pages = {313-319}, orcid-numbers = {Zombori, Tamás/0000-0002-0654-563X; Tiszlavicz, László/0000-0003-1134-6587; Cserni, Gábor/0000-0003-1344-7744; Furák, József/0000-0002-7224-1642} }